ArticleBMC cancer2025
Identification and modulation of a PI3K/AKT/mTOR pathway-targeting microRNA in order to increase colorectal cancer cells radiosensitivity in vitro.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Targeting molecular and genetic pathways driving tumorigenesis for precision therapy in colorectal cancer.Cancer biology & therapy · 2026Review
- Mechanism of miR-188-5p enhancing radioresistance in nasopharyngeal carcinoma by targeting PTEN to activate the PI3K/Akt signaling pathway.Translational cancer research · 2026Article
- MicroRNA-Mediated Regulation of Ionizing Radiation Responses: Mechanisms and Advances in Clinical Translation.Current issues in molecular biology · 2026Review
- Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications.Cancers · 2026Review
- Adipocyte-Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15-Mediated S-Palmitoylation of PPARγ.Cancer science · 2026Article
- Nucleic Acid Therapeutics for "Undruggable" Cancer Targets: Mechanisms, Challenges, and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- miR‑16‑5p Protects RGCs Against Retinal Ischemia-Reperfusion Injury by Modulating Astrocyte-Mediated Neuroinflammation Through the Wip1/NF-κB Signaling Axis.Molecular neurobiology · 2026Article
- C5aR1 and cGAS/STING and their possible involvement in radiosensitivity of colorectal cancer.iScience · 2026Review
- Tumor microenvironment-driven microRNA dysregulation: Key interactions in colorectal cancer progression.World journal of gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe progression of colorectal cancer (CRC) occurs via the PI3K/AKT/mTOR signaling pathway. Recent evidence suggests that microRNAs (miRNAs) can modulate gene expression, potentially offering new treatment options. This study aims to identify a miRNA that enhances radiosensitivity in CRC by targeting the PI3K/AKT/mTOR signaling pathway.
methodsGene expression datasets of CRC patients were retrieved from the NCBI database. Genes from the PI3K/AKT/mTOR signaling pathway were identified using the KEGG database. miRNA-mRNA binding sites were determined using TarBase, miRTarBase, mirDIP and miRNet. The selected miRNA was transfected into CRC cell lines, focusing on the two most responsive lines. Radiosensitivity was assessed by clonogenic assays and analysis of apoptotic cells in both irradiated and non-irradiated groups. Changes in gene expression were analyzed by real-time PCR.
resultsData from 87 CRC patients were extracted and revealed 20 genes associated with the pathway according to specific criteria (logFC > 0 and adj.P < 0.05).miR-16-5p was selected for further investigation. The optimal transfection time was set at 48 h, with LoVo and HT-29 selected as cell lines. Irradiation with 4 Gy significantly suppressed miR-16-5p in both lines (P < 0.0023 for LoVo; P < 0.0001 for HT-29). miR-16-5p effectively suppressed the target genes CCNE1, CCND1, MYC, CDK4, HSP90AB1 and PIK3CA, with remarkable changes in gene expression after irradiation. Transfection and irradiation decreased cell survival (P < 0.05) and increased apoptosis (P < 0.0001).
conclusionThe PI3K/AKT/mTOR signalling pathway is associated with radioresistance in CRC. miR-16-5p represses pathway genes and increases radiosensitivity, suggesting that miRNA-based gene therapy may improve treatment outcomes and patient quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.